Evidence map›Paper›PMID 36696889›Full record

ArticlePathobiology : journal of immunopathology, molecular and cellular biology2023

Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.

Dávid Semjén, Borbála Dénes, Áron Somorácz, Attila Fintha, Gertrúd Forika, Alex Jenei, Deján Dobi, Tamás Micsik, Kornélia Veronika Eizler, Nándor Giba and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Dávid SemjénDepartment of Pathology, Medical School and Clinical Centre, University of Pécs, Pécs, Hungary.
Borbála DénesMedServ Ltd., Budapest, Hungary.
Áron SomoráczMedServ Ltd., Budapest, Hungary.
Attila FinthaDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Gertrúd ForikaDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Alex JeneiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Deján DobiDepartment of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
Tamás MicsikPathology Unit, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.
Kornélia Veronika EizlerPathology Unit, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.
Nándor GibaPathology Unit, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.
Fanni SántaDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Anita SejbenDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Béla IványiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Levente KuthiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Semmelweis University · HUUniversity of Szeged · HUFejér Megyei Szent György Egyetemi Oktató Kórház · HUBudapest University of Economics and Business · HUUniversity of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEnd-stage renal disease (ESRD) and acquired cystic kidney disease (ACKD) are known risk factors for renal cell carcinoma (RCC). Hereby, the clinicopathological features of RCCs developed in ESRD were investigated.

methodsA database consisting of 34 tumors from 31 patients with ESRD among 2,566 nephrectomy samples of RCC was built. The demographic, clinical, and follow-up data along with pathological parameters were analyzed. The RCCs were diagnosed according to the current WHO Classification of Urinary and Male Genital Tumors.

resultsTwenty-two tumors developed in men and 12 in women, with a median age of 56 years (range: 27-75 years). The causes of ESRD were glomerulonephritis (n = 7), hypertensive kidney disease (n = 6), autosomal dominant polycystic kidney disease (n = 6), chronic pyelonephritis (n = 4), diabetic nephropathy (n = 3), chemotherapy-induced nephropathy (n = 1), and undetermined (n = 4). ACKD complicated ESRD in 12 patients. The following histological subtypes were identified: clear cell RCC (n = 19), papillary RCC (n = 5), clear cell papillary tumor (n = 5), ACKD RCC (n = 3), and eosinophilic solid and cystic RCC (n = 2). The median tumor size was 31 mm (range: 10-80 mm), and 32 tumors were confined to the kidney (pT1-pT2). There was no tumor-specific death during the period of this study. Progression was registered in 1 patient.

conclusionIn our cohort, the most common RCC subtype was clear cell RCC (55%), with a frequency that exceeded international data appreciably (14-25%). The incidence of clear cell papillary tumor and ACKD RCC (14.7% and 8.5%) was lower than data reported in the literature (30% and 40%). Our results indicate a favorable prognosis of RCC in ESRD.

Indexed as

Carcinoma, Renal CellKidney Failure, ChronicKidney NeoplasmsAdultAgedFemaleHumansHungaryMaleMiddle AgedRetrospective StudiesAcquired cystic kidney diseaseEnd-stage renal diseaseRenal cell carcinoma

Identifiers

PMID36696889
PMCPMC10614572
OpenAlexW4318035637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.